In addition, Yuan et al. [11] found that the expression level of CD276 in a prostate cancer group was significantly higher compared with that in the associated benign prostatic hyperplasia group, and knockdown of CD276 led to a marked reduction in the migratory and invasive capabilities of prostate cancer cells, thereby demonstrating that CD276 has an important role in the progression of prostate cancer. The gene discussed is CD276; the disease is prostate carcinoma.